Needham & Company LLC restated their hold rating on shares of Gilead Sciences (NASDAQ:GILD – Free Report) in a research report sent to investors on Wednesday,Benzinga reports. Other analysts also ...

Shares of Gilead Sciences ( GILD -1.77%) were jumping 7.9% higher on Wednesday at 11:34 a.m. The solid gain came after the ...

Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) will be announcing earnings results tomorrow afternoon. Here’s what to expect. Gilead Sciences beat analysts’ revenue expectations by 7. ...

Maxim Group analyst Michael Okunewitch maintained a Hold rating on Gilead Sciences (GILD – Research Report) today. The company’s shares closed ...

In a report released today, Matthew Biegler from Oppenheimer reiterated a Buy rating on Gilead Sciences (GILD – Research Report), with a price ...

In the latest market close, Gilead Sciences (GILD) reached $98.38, with a +1.21% movement compared to the previous day. The stock outpaced the S&P 500's daily loss of 0.76%. Elsewhere, the Dow saw ...

Investors with a lot of money to spend have taken a bullish stance on Gilead Sciences GILD. And retail traders should know. We noticed this today when the trades showed up on publicly available ...

What Happened? Shares of biopharmaceutical company Gilead Sciences (NASDAQ:GILD) jumped 8.6% in the morning session after the ...

Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) – Zacks Research boosted their Q2 2025 earnings per share estimates for Gilead Sciences in a report issued on Thursday, January 16th.